Skip to main content
HUM logo

HUM · Humana Inc

Track HUM — free
$411.79 -5.63 (-1.35%) At close · Nov 5 Earnings today
Market Cap
$50.12B
Shares
120.06M
Volume · Nov 5 1.36M Avg daily vol (3M) 1.25M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$411.79 Open$417.47 Day$405.40–423.97 52W close$163.67–433.50 Avg vol 30d1.6M Short int3.7M · 3.1% of shares · 2.0d Short vol43% Last earningsNov 6, 2026 DataJan 2020–Nov 2026 Filing10-Q · Jul 29

Up next

Nov 6, 2026 Announced · this week
Nov 6, 2026 Today Open the call

Latest documents

2026
Oct 13
Current report 8-K
Regulation FD disclosure

Humana entered a majority-owned BlackRock joint venture managing nearly 150 CenterWell Senior Primary Care clinics, replacing existing joint ventures and expected to reduce liabilities and cost of capital. Humana affirmed FY 2026 adjusted EPS guidance of at least $9.00.

Oct 9
Current report 8-K
Regulation FD disclosure

Humana Inc. says final 2027 Medicare Advantage Star Ratings data show it exceeded its Top Quartile goal, expects a one-time 2028 benefit for one-time investments and shareholder returns, and affirms at least $9.00 adjusted EPS for FY 2026.

Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $40.87B ▲ 26.2% Net income $694M ▲ 27.3% Diluted EPS $5.73 ▲ 27.1%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$145.68B
Trailing 12 months
Net income (TTM)
$1.28B
Trailing 12 months
Revenue growth YoY
+26.2%
Year over year
Operating margin
1.9%
Trailing 12 months
P / E (TTM)
39.4
Trailing earnings · reciprocal yield 2.5%
FCF yield
3.9%
TTM · current market cap
Return on invested capital
22.8%
Trailing 12 months
Net cash
$9.62B
Latest balance sheet
Dividend yield
0.8%
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
+48.1%
Trailing year
Short interest
3.1%
Latest settlement · 2.0 days to cover
View all 122 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Humana reported 2Q26 Adjusted EPS of $7.61 and affirmed full-year 2026 Adjusted EPS guidance of at least $9.00 (revising GAAP EPS guidance down to at least $6.52 from at least $8.36), while signaling meaningful margin expansion ahead as 2027 MA bids target a sustainable pre-tax margin of at least 3% by 2028.

Bullish
  • + Reported 2Q26 Adjusted EPS of $7.61 at the high end of expectations (80%-85% of FY)
  • + Individual MA membership grew ~23% YTD, tracking to ~25% FY growth target
  • + Strategic expansion via $900M Gentiva divestiture funding MaxHealth acquisition and new statewide Illinois Medicaid contract
  • + CenterWell Senior Primary Care patients grew 27% YTD with strong retention and NPS gains
Bearish
  • − Revised FY 2026 GAAP EPS guidance down to at least $6.52 from at least $8.36
  • − 2027 plan exits will impact approximately 600,000 members
  • − Prior period medical claims reserve development was less favorable at $53M in 2Q26 vs $161M in 2Q25

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.6 · calm Equity put/call 0.44
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +32%
above
Price vs 50-day avg +2%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 92%
near high
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +35%
trailing
YTD return +61%
this year
Relative strength +36%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $403 › 200d $311 — 50d above 200d
Institutional flow Accumulating
433 of 943 funds reported for Sep 30 · net +972.5K sh shares · +56 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.05% of shares out · ▲ +31.4% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
943 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Fair
Revenue growth +10%
Y/Y
EPS growth −1%
Y/Y
Free cash flow $375.0M
Valuation P/E 39.4
rich
Buyback $2.7B
remaining
Balance sheet $8.2B
net debt
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −42%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 8
Latest guidance · from the Earnings Call filed Jul 29, 2026
Gentiva minority interest divestiture value · fourth quarter 2026 $900M
Previous outlook earlier release · from the 8-K filed Apr 29, 2026

Still-open targets the latest release did not restate under the same label.

GAAP · FY 2026 at least $8.36
Adjusted (non-GAAP) · FY 2026 at least $9.00
Change in year-end medical membership - Individual Medicare Adva · FY 2026 25%
Individual MA membership growth · FY 2026 25%
Prior guidance period ended · from the 8-K filed Jul 29, 2026
Adjusted EPS · third quarter $-1.00
Benefit ratio (Insurance segment) for third quarter · third quarter at least 94%
Guided vs delivered · last 8 settled
GAAP diluted earnings per share FY 2024
guided $12.81
$9.98 Miss −22.1%
Total Revenues Consolidated Full Year 2024
guided $116B
$117.76B Beat +1.5%
GAAP EPS FY 2023
guided at least $26.31
$20.00 Miss −24.0%
Total Revenues Consolidated GAAP Full Year 2023
guided $104.4B – $106.4B
$106.37B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+32% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $403 › 200d $311 — 50d above 200d
Institutional flow Accumulating
433 of 943 funds reported for Sep 30 · net +972.5K sh shares · +56 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.05% of shares out · ▲ +31.4% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
943 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $164 Now $412 · 92% Range high $434
vs 200-day avg +32% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Healthcare Plans — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HUM
Humana Inc
this stock
$50.12B +60.8% +10.1% 39.4 3.1%
UNH
Unitedhealth Group Inc
$354.57B +19.9% +11.8% 22.6 1.6%
CVS
CVS HEALTH Corp
$102.31B +2.5% +7.8% 9.3 1.3%
ELV
Elevance Health, Inc.
$93.81B +23.2% +12.5% 18.4 2.4%
CI
Cigna Group
$80.70B +9.5% +11.2% 13.5 2.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
967
% held
105.3%
Reported
433 of 943
Top holder
Dodge & Cox
Held Float
View
Held by Funds
Fund positions
873
View
Short & Settlement
Short Interest Rising
Shares short
3.7M
Days to cover
2.0d
Change
+875.8K sh
View
Short Volume
Short vol %
43%
As of
Nov 5, 2026
Short Total
View
Fails to Deliver
FTD shares
2.6K
Value
$1.0M
As of
Sep 21, 2026
View
Off-Exchange
Off-exchange %
51.0%
Week of
Sep 28, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$129.7B
Net income (FY)
$1.2B
EPS diluted
$9.84
View
Buybacks
Authorized
$3.0B
Remaining
$2.7B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 13, 2026
This year
21

Humana entered a majority-owned BlackRock joint venture managing nearly 150 CenterWell Senior Primary Care clinics, replacing existing joint ventures and expected to reduce liabilities and cost of capital. Humana affirmed FY 2026 adjusted EPS guidance of at least $9.00.

View
Proposed Sales
Value
$2.7M
Shares
11.0K
Filed
Apr 8, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 6, 2026
Last webcast
Jul 29, 2026
View
Investor Relations
Latest news
Humana Inc. to Release Third Quar…
Published
Oct 12, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
HUM -1.4% +6.4% +35.0% -0.7% +60.8%
SPY -4.7% -5.3% -0.8% -3.0% +7.5%
vs SPY +3.4% +11.7% +35.8% +2.4% +53.3%

Capital returns

Latest dividend
$0.885 / share · ex Oct 30, 2026
Declared · upcoming
$0.885 / share · ex Dec 24, 2026
Raised 12.3%
Paid (TTM)
$3.54 / share · 4 payouts
Dividend yield (TTM, derived)
0.86%
Full dividend history
Buyback program · as of Jul 28, 2026
Authorized
$3.00B
Spent (derived)
$300.00M
Remaining
$2.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 49071 CUSIP 444859102 13F (30d) 433 filings 394 filers Visit website Investor relations